MC4R dimerization in the paraventricular nucleus and GHSR/MC3R heterodimerization in the arcuate nucleus: Is there relevance for body weight regulation?

Neuroendocrinology

Volumn 95, Issue 4, 2012, Pages 277-288

  Rediger, Anne ^a   Piechowski, Carolin Leonie ^a   Habegger, Kirk ^b   Grüters, Annette ^a   Krude, Heiko ^a   Tschöp, Matthias H ^b   Kleinau, Gunnar ^a   Biebermann, Heike ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Dimerization; G protein coupled receptor; Growth hormone secretagogue receptor; Melanocortin 3 receptor; Melanocortin 4 receptor; Weight regulation

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; 2,4 DIAMINOPYRIMIDINE DERIVATIVE; ALPHA INTERMEDIN DERIVATIVE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BIM 28163; G PROTEIN COUPLED RECEPTOR; GHRELIN RECEPTOR; GROWTH HORMONE SECRETAGOGUE RECEPTOR; GROWTH HORMONE SECRETAGOGUE RECEPTOR ANTAGONIST; IBUTAMOREN; IRC 022493; IRC 022511; ISOXAZOLE DERIVATIVE; L NOX B11; LEPTIN; MELANOCORTIN; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR AGONIST; MELANOCORTIN 4 RECEPTOR ANTAGONIST; MELANOCORTIN RECEPTOR AGONIST; MELANOCORTIN RECEPTOR ANTAGONIST; MK 0493; OXINDOLE; PIPERAZINE; QUINAZOLINE DERIVATIVE; RECEPTOR BLOCKING AGENT; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APPETITE; ARCUATE NUCLEUS; BODY WEIGHT; CACHEXIA; DIMERIZATION; DRUG TARGETING; FOOD INTAKE; GENE MUTATION; GROWTH HORMONE RELEASE; HORMONE ACTION; HUMAN; LIGAND BINDING; NONHUMAN; OBESITY; PARAVENTRICULAR THALAMIC NUCLEUS; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; WEIGHT CONTROL;

ANIMALS; APPETITE REGULATION; ARCUATE NUCLEUS; BODY WEIGHT; HUMANS; MODELS, BIOLOGICAL; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PROTEIN MULTIMERIZATION; RECEPTOR, MELANOCORTIN, TYPE 3; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, GHRELIN;

EID: 84862762848     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000334903     Document Type: Review

References (101)

1. Bernard C: Leçons sur les phénomènes de la vie communs aux animaux et aux végétaux. 2. Paris: Ballieres, 1878-1879.
2. Cannon WB: Physiological regulation of normal states: Some tentative postulates concerning biological homeostatics. Editions Medicales 1926; Jubilee volume to Charles Richet, 91-93.
3. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
4. Flier JS: Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337-350.
5. Kojima S, Ueno N, Asakawa A, Sagiyama K, Naruo T, Mizuno S, Inui A: A role for pancreatic polypeptide in feeding and body weight regulation. Peptides 2007;28:459-463.
6. Tschop M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature 2000;407:908-913.
7. Williams DL, Cummings DE: Regulation of ghrelin in physiologic and pathophysiologic states. J Nutr 2005;135:1320-1325.
8. Tschop M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R, Folwaczny C: Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001;24:RC19-21.
9. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS: Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 2002;8:643-644.
10. Haqq AM, Stadler DD, Rosenfeld RG, Pratt KL, Weigle DS, Frayo RS, LaFranchi SH, Cummings DE, Purnell JQ: Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2003;88:3573-3576.
11. Horvath TL, Diano S, Tschop M: Ghrelin in hypothalamic regulation of energy balance. Curr Top Med Chem 2003;3:921-927.
12. Kirchner H, Gutierrez JA, Solenberg PJ, Pfluger PT, Czyzyk TA, Willency JA, Schurmann A, Joost HG, Jandacek RJ, Hale JE, Heiman ML, Tschop MH: Goat links dietary lipids with the endocrine control of energy balance. Nat Med 2009;15:741-745.
13. Cone RD: Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005;8:571-578.
14. Barsh GS, Schwartz MW: Genetic approaches to studying energy balance: Perception and integration. Nat Rev Genet 2002;3:589-600.
15. Schwartz MW, Woods SC, Seeley RJ, Barsh GS, Baskin DG, Leibel RL: Is the energy homeostasis system inherently biased toward weight gain? Diabetes 2003;52:232-238.
16. Barsh GS, Farooqi IS, O'Rahilly S: Genetics of body-weight regulation. Nature 2000;404:644-651.
17. Barth N, Ziegler A, Himmelmann GW, Coners H, Wabitsch M, Hennighausen K, Mayer H, Remschmidt H, Schafer H, Hebebrand J: Significant weight gains in a clinical sample of obese children and adolescents between 1985 and 1995. Int J Obes Relat Metab Disord 1997;21:122-126.
18. Dalrymple MB, Pfleger KD, Eidne KA: G protein-coupled receptor dimers: Functional consequences, disease states and drug targets. Pharmacol Ther 2008;118:359-371.
19. Bagnol D: G protein-coupled receptors in hypothalamic circuits involved in metabolic diseases. Curr Opin Drug Discov Devel 2004;7:665-682.
20. Regard JB, Sato IT, Coughlin SR: Anatomical profiling of G protein-coupled receptor expression. Cell 2008;135:561-571.
21. Schioth HB: G protein-coupled receptors in regulation of body weight. CNS Neurol Disord Drug Targets 2006;5:241-249.
22. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, DelValle J, Yamada T: Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993;268:8246-8250.
23. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997;88:131-141.
24. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S: Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003;348:1085-1095.
25. Tao YX: The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 2010;31:506-543.
26. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao L, Metzger JM, Strack AM, Camacho RE, Mellin TN, Nunes CN, Min W, Fisher J, Gopal-Truter S, MacIntyre DE, Chen HY, Van der Ploeg LH: Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000;26:97-102.
27. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, Baetscher M, Cone RD: A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000;141:3518-3521.
28. Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL, Cone RD, Low MJ: Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001;411:480-484.
29. Marks DL, Hruby V, Brookhart G, Cone RD: The regulation of food intake by selective stimulation of the type 3 melanocortin receptor (mc3r). Peptides 2006;27:259-264.
30. Tarnow P, Schoneberg T, Krude H, Gruters A, Biebermann H: Mutationally induced disulfide bond formation within the third extracellular loop causes melanocortin 4 receptor inactivation in patients with obesity. J Biol Chem 2003;278:48666-48673.
31. Schioth HB, Petersson S, Muceniece R, Szardenings M, Wikberg JE: Deletions of the N-terminal regions of the human melanocortin receptors. FEBS Lett 1997;410:223-228.
32. Yang YK, Fong TM, Dickinson CJ, Mao C, Li JY, Tota MR, Mosley R, Van Der Ploeg LH, Gantz I: Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry 2000;39:14900-14911.
33. Srinivasan S, Lubrano-Berthelier C, Govaerts C, Picard F, Santiago P, Conklin BR, Vaisse C: Constitutive activity of the melanocortin-4 receptor is maintained by its Nterminal domain and plays a role in energy homeostasis in humans. J Clin Invest 2004;114:1158-1164.
34. Yang Y: Structure, function and regulation of the melanocortin receptors. Eur J Pharmacol 2011;660:125-130.
35. Chen M, Aprahamian CJ, Celik A, Georgeson KE, Garvey WT, Harmon CM, Yang Y: Molecular characterization of human melanocortin-3 receptor ligand-receptor interaction. Biochemistry 2006;45:1128-1137.
36. Chen M, Cai M, Aprahamian CJ, Georgeson KE, Hruby V, Harmon CM, Yang Y: Contribution of the conserved amino acids of the melanocortin-4 receptor in [corrected] [nle4,d-phe7]-alpha-melanocyte-stimulating [corrected] hormone binding and signaling. J Biol Chem 2007;282:21712-21719.
37. Tan K, Pogozheva ID, Yeo GS, Hadaschik D, Keogh JM, Haskell-Leuvano C, O'Rahilly S, Mosberg HI, Farooqi IS: Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor. Endocrinology 2009;150:114-125.
38. Yang Y, Chen M, Lai Y, Gantz I, Yagmurlu A, Georgeson KE, Harmon CM: Molecular determination of agouti-related protein binding to human melanocortin-4 receptor. Mol Pharmacol 2003;64:94-103.
39. van der Lely AJ, Tschop M, Heiman ML, Ghigo E: Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004;25:426-457.
40. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW: High constitutive signaling of the ghrelin receptor-identification of a potent inverse agonist. Mol Endocrinol 2003;17:2201-2210.
41. Holst B, Holliday ND, Bach A, Elling CE, Cox HM, Schwartz TW: Common structural basis for constitutive activity of the ghrelin receptor family. J Biol Chem 2004;279:53806-53817.
42. Holst B, Nygaard R, Valentin-Hansen L, Bach A, Engelstoft MS, Petersen PS, Frimurer TM, Schwartz TW: A conserved aromatic lock for the tryptophan rotameric switch in tm-vi of seven-transmembrane receptors. J Biol Chem 2010;285:3973-3985.
43. Holst B, Mokrosinski J, Lang M, Brandt E, Nygaard R, Frimurer TM, Beck-Sickinger AG, Schwartz TW: Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem 2007;282:15799-15811.
44. Holst B, Frimurer TM, Mokrosinski J, Halkjaer T, Cullberg KB, Underwood CR, Schwartz TW: Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor. Mol Pharmacol 2009;75:44-59.
45. Holst B, Schwartz TW: Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends Pharmacol Sci 2004;25:113-117.
46. Sun Y, Wang P, Zheng H, Smith RG: Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 2004;101:4679-4684.
47. Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, Jones JE, Deysher AE, Waxman AR, White RD, Williams TD, Lachey JL, Seeley RJ, Lowell BB, Elmquist JK: Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005;115:3564-3572.
48. Wang HJ, Geller F, Dempfle A, Schauble N, Friedel S, Lichtner P, Fontenla-Horro F, Wudy S, Hagemann S, Gortner L, Huse K, Remschmidt H, Bettecken T, Meitinger T, Schafer H, Hebebrand J, Hinney A: Ghrelin receptor gene: identification of several sequence variants in extremely obese children and adolescents, healthy normal-weight and underweight students, and children with short normal stature. J Clin Endocrinol Metab 2004;89:157-162.
49. Liu G, Fortin JP, Beinborn M, Kopin AS: Four missense mutations in the ghrelin receptor result in distinct pharmacological abnormalities. J Pharmacol Exp Ther 2007;322:1036-1043.
50. Pantel J, Legendre M, Nivot S, Morisset S, Vie-Luton MP, le Bouc Y, Epelbaum J, Amselem S: Recessive isolated growth hormone deficiency and mutations in the ghrelin receptor. J Clin Endocrinol Metab 2009;94:4334-4341.
51. Inoue H, Kangawa N, Kinouchi A, Sakamoto Y, Kimura C, Horikawa R, Shigematsu Y, Itakura M, Ogata T, Fujieda K: Identification and functional analysis of novel human growth hormone secretagogue receptor (GHSR) gene mutations in Japanese subjects with short stature. J Clin Endocrinol Metab 2011;96:E373-E378.
52. Fehm HL, Smolnik R, Kern W, McGregor GP, Bickel U, Born J: The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab 2001;86:1144-1148.
53. Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE, Gruters A: Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 2003;88:4633-4640.
54. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997;385:165-168.
55. Van der Ploeg LH, Martin WJ, Howard AD, Nargund RP, Austin CP, Guan X, Drisko J, Cashen D, Sebhat I, Patchett AA, Figueroa DJ, DiLella AG, Connolly BM, Weinberg DH, Tan CP, Palyha OC, Pong SS, MacNeil T, Rosenblum C, Vongs A, Tang R, Yu H, Sailer AW, Fong TM, Huang C, Tota MR, Chang RS, Stearns R, Tamvakopoulos C, Christ G, Drazen DL, Spar BD, Nelson RJ, MacIntyre DE: A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA 2002;99:11381-11386.
56. Sebhat IK, Martin WJ, Ye Z, Barakat K, Mosley RT, Johnston DB, Bakshi R, Palucki B, Weinberg DH, MacNeil T, Kalyani RN, Tang R, Stearns RA, Miller RR, Tamvakopoulos C, Strack AM, McGowan E, Cashen DE, Drisko JE, Hom GJ, Howard AD, MacIntyre DE, van der Ploeg LH, Patchett AA, Nargund RP: Design and pharmacology of n-[(3r)-1,2,3, 4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1r)- 1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1h-1,2,4-triazol- 1-ylmethyl)piperidin-1- yl]- 2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J Med Chem 2002;45:4589-4593.
57. Guo L, Ye Z, Liu J, He S, Bakshi RK, Sebhat IK, Dobbelaar PH, Hong Q, Jian T, Dellureficio JP, Tsou NN, Ball RG, Weinberg DH, MacNeil T, Tang R, Tamvakopoulos C, Peng Q, Chen HY, Chen AS, Martin WJ, MacIntyre DE, Strack AM, Fong TM, Wyvratt MJ, Nargund RP: Discovery of potent, selective, and orally bioavailable 3h-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists. Bioorg Med Chem Lett 2010;20:4895-4900.
58. He S, Ye Z, Dobbelaar PH, Sebhat IK, Guo L, Liu J, Jian T, Lai Y, Franklin CL, Bakshi RK, Dellureficio JP, Hong Q, Weinberg DH, Macneil T, Tang R, Strack AM, Tamvakopoulos C, Peng Q, Miller RR, Stearns RA, Chen HY, Chen AS, Fong TM, Wyvratt MJ, Jr, Nargund RP: Spiroindane based amides as potent and selective mc4r agonists for the treatment of obesity. Bioorg Med Chem Lett 2010;20:4399-4405.
59. He S, Ye Z, Dobbelaar PH, Sebhat IK, Guo L, Liu J, Jian T, Lai Y, Franklin CL, Bakshi RK, Dellureficio JP, Hong Q, Tsou NN, Ball RG, Cashen DE, Martin WJ, Weinberg DH, Macneil T, Tang R, Tamvakopoulos C, Peng Q, Miller RR, Stearns RA, Chen HY, Chen AS, Strack AM, Fong TM, Macintyre DE, Wyvratt MJ Jr, Nargund RP: Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist. Bioorg Med Chem Lett 2010;20:2106-2110.
60. Roubert P, Dubern B, Plas P, Lubrano-Berthelier C, Alihi R, Auger F, Deoliveira DB, Dong JZ, Basdevant A, Thurieau C, Clement K: Novel pharmacological mc4r agonists can efficiently activate mutated mc4r from obese patient with impaired endogenous agonist response. J Endocrinol 2010;207:177-183.
61. Fong TM, Strack AM: Melanocortin-4 receptor as a new target for drug development. Handbook of Obesity 2008;3rd edn:389-394.
62. Krishna R, Gumbiner B, Stevens C, Musser B, Mallick M, Suryawanshi S, Maganti L, Zhu H, Han TH, Scherer L, Simpson B, Cosgrove D, Gottesdiener K, Amatruda J, Rolls BJ, Blundell J, Bray GA, Fujioka K, Heymsfield SB, Wagner JA, Herman GA: Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 2009;86:659-666.
63. Peter JC, Lecourt AC, Weckering M, Zipfel G, Niehoff ML, Banks WA, Hofbauer KG: A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: Effectiveness after peripheral and central administration. J Pharmacol Exp Ther 2010;333:478-490.
64. Weyermann P, Dallmann R, Magyar J, Anklin C, Hufschmid M, Dubach-Powell J, Courdier-Fruh I, Hennebohle M, Nordhoff S, Mondadori C: Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS One 2009;4:e4774.
65. Nogueiras R, Perez-Tilve D, Wortley KE, Tschop M: Growth hormone secretagogue (ghrelin-) receptors - a complex drug target for the regulation of body weight. CNS Neurol Disord Drug Targets 2006;5:335-343.
66. Muller TD, Perez-Tilve D, Tong J, Pfluger PT, Tschop MH: Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia. J Cachex Sarcopenia Muscle 2010;1:159-167.
67. Rudolph J, Esler WP, O'Connor S, Coish PD, Wickens PL, Brands M, Bierer DE, Bloomquist BT, Bondar G, Chen L, Chuang CY, Claus TH, Fathi Z, Fu W, Khire UR, Kristie JA, Liu XG, Lowe DB, McClure AC, Michels M, Ortiz AA, Ramsden PD, Schoenleber RW, Shelekhin TE, Vakalopoulos A, Tang W, Wang L, Yi L, Gardell SJ, Livingston JN, Sweet LJ, Bullock WH: Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. J Med Chem 2007;50:5202-5216.
68. Moulin A, Demange L, Berge G, Gagne D, Ryan J, Mousseaux D, Heitz A, Perrissoud D, Locatelli V, Torsello A, Galleyrand JC, Fehrentz JA, Martinez J: Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations. J Med Chem 2007;50:5790-5806.
69. Demange L, Boeglin D, Moulin A, Mousseaux D, Ryan J, Berge G, Gagne D, Heitz A, Perrissoud D, Locatelli V, Torsello A, Galleyrand JC, Fehrentz JA, Martinez J: Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor 1. J Med Chem 2007;50:1939-1957.
70. Zhao H, Xin Z, Patel JR, Nelson LT, Liu B, Szczepankiewicz BG, Schaefer VG, Falls HD, Kaszubska W, Collins CA, Sham HL, Liu G: Structure-activity relationship studies on tetralin carboxamide growth hormone secretagogue receptor antagonists. Bioorg Med Chem Lett 2005;15:1825-1828.
71. Zhao H, Xin Z, Liu G, Schaefer VG, Falls HD, Kaszubska W, Collins CA, Sham HL: Discovery of tetralin carboxamide growth hormone secretagogue receptor antagonists via scaffold manipulation. J Med Chem 2004;47:6655-6657.
72. Xin Z, Zhao H, Serby MD, Liu B, Schaefer VG, Falls DH, Kaszubska W, Colins CA, Sham HL, Liu G: Synthesis and structure-activity relationships of isoxazole carboxamides as growth hormone secretagogue receptor antagonists. Bioorg Med Chem Lett 2005;15:1201-1204.
73. Liu B, Liu M, Xin Z, Zhao H, Serby MD, Kosogof C, Nelson LT, Szczepankiewicz BG, Kaszubska W, Schaefer VG, Falls HD, Lin CW, Collins CA, Sham HL, Liu G: Optimization of 2,4-diaminopyrimidines as GHS-R antagonists: Side chain exploration. Bioorg Med Chem Lett 2006;16:1864-1868.
74. Tokunaga T, Hume WE, Nagamine J, Kawamura T, Taiji M, Nagata R: Structure-activity relationships of the oxindole growth hormone secretagogues. Bioorg Med Chem Lett 2005;15:1789-1792.
75. Yu M, Lizarzaburu M, Beckmann H, Connors R, Dai K, Haller K, Li C, Liang L, Lindstrom M, Ma J, Motani A, Wanska M, Zhang A, Li L, Medina JC: Identification of piperazine-bisamide ghsr antagonists for the treatment of obesity. Bioorg Med Chem Lett 2010;20:1758-1762.
76. Zhai W, Flynn N, Longhi DA, Tino JA, Murphy BJ, Slusarchyk D, Gordon DA, Pendri A, Shi S, Stoffel R, Ma B, Sofia MJ, Gerritz SW: Discovery and optimization of (r)-prolinol-derived agonists of the growth hormone secretagogue receptor (GHSR). Bioorg Med Chem Lett 2008;18:5083-5086.
77. Halem HA, Taylor JE, Dong JZ, Shen Y, Datta R, Abizaid A, Diano S, Horvath TL, Culler MD: A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain. Neuroendocrinology 2005;81:339-349.
78. Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA, Kasuga M: Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003;52:947-952.
79. Helmling S, Maasch C, Eulberg D, Buchner K, Schroder W, Lange C, Vonhoff S, Wlotzka B, Tschop MH, Rosewicz S, Klussmann S: Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc Natl Acad Sci USA 2004;101:13174-13179.
80. Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, Meijler MM, Janda KD: Vaccination against weight gain. Proc Natl Acad Sci USA 2006;103:13226-13231.
81. Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE, Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO: Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008;149:601-611.
82. Blackman MR: Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med 2008;149:677-679.
83. Druce MR, Wren AM, Park AJ, Milton JE, Patterson M, Frost G, Ghatei MA, Small C, Bloom SR: Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) 2005;29:1130-1136.
84. Rediger A, Tarnow P, Bickenbach A, Schaefer M, Krude H, Gruters A, Biebermann H: Heterodimerization of hypothalamic G-protein- coupled receptors involved in weight regulation. Obes Facts 2009;2:80-86.
85. Agnati LF, Fuxe K, Zini I, Lenzi P, Hokfelt T: Aspects on receptor regulation and isoreceptor identification. Med Biol 1980;58:182-187.
86. White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, Barnes AA, Emson P, Foord SM, Marshall FH: Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 1998;396:679-682.
87. Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin MM, Dai M, Yao WJ, Johnson M, Gunwaldsen C, Huang LY, Tang C, Shen Q, Salon JA, Morse K, Laz T, Smith KE, Nagarathnam D, Noble SA, Branchek TA, Gerald C: GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 1998;396:674-679.
88. Kaupmann K, Huggel K, Heid J, Flor PJ, Bischoff S, Mickel SJ, McMaster G, Angst C, Bittiger H, Froestl W, Bettler B: Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature 1997;386:239-246.
89. Pin JP, Kniazeff J, Liu J, Binet V, Goudet C, Rondard P, Prezeau L: Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J 2005;272:2947-2955.
90. Bouvier M: Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci 2001;2:274-286.
91. Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, Jockers R: Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem 2002;277:21522-21528.
92. George SR, O'Dowd BF, Lee SP: G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002;1:808-820.
93. Biebermann H, Krude H, Elsner A, Chubanov V, Gudermann T, Gruters A: Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 2003;52:2984-2988.
94. Elsner A, Tarnow P, Schaefer M, Ambrugger P, Krude H, Gruters A, Biebermann H: MC4R oligomerizes independently of extracellular cysteine residues. Peptides 2006;27:372-379.
95. Rediger A, Piechowski CL, Yi CX, Tarnow P, Strotmann R, Grueters A, Krude H, Schoeneberg T, Tschoep MH, Kleinau G, Biebermann H: Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin- and melanocortin-3 receptors. J Biol Chem 2011;286:39623-39631.
96. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, Lohse MJ, Milligan G, Palczewski K, Parmentier M, Spedding M: International union of basic and clinical pharmacology. Lxvii. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev 2007;59:5-13.
97. Hoek JB, Taraschi TF, Rubin E: Functional implications of the interaction of ethanol with biologic membranes: Actions of ethanol on hormonal signal transduction systems. Semin Liver Dis 1988;8:36-46.
98. Terrillon S, Bouvier M: Roles of G-protein-coupled receptor dimerization. EMBO Rep 2004;5:30-34.
99. Jacoby E, Bouhelal R, Gerspacher M, Seuwen K: The 7 TM G-protein-coupled receptor target family. ChemMedChem 2006;1:761-782.
100. McGraw DW, Mihlbachler KA, Schwarb MR, Rahman FF, Small KM, Almoosa KF, Liggett SB: Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest 2006;116:1400-1409.
101. Barnes PJ: Pharmacology of airway smooth muscle. Am J Respir Crit Care Med 1998;158:S123-S132.